PDS Biotech adds NantWorks founder Patrick Soon-Shiong to board under PIPE deal

• PDS Biotech added Dr. Patrick Soon-Shiong to its board under a PIPE led by Nant Capital.
• Soon-Shiong is a physician-scientist, biotech entrepreneur, investor, former developer of an FDA-approved immunocytokine.
• Nant can designate a second director while it owns at least 15% of outstanding common stock, subject to a 19.9% cap.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-035853), on September 08, 2026, and is solely responsible for the information contained therein.